Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.40B P/E - EPS this Y 109.10% Ern Qtrly Grth -
Income -73.52M Forward P/E 85.85 EPS next Y 350.00% 50D Avg Chg -2.00%
Sales 287.61M PEG - EPS past 5Y - 200D Avg Chg 102.00%
Dividend N/A Price/Book 8.70 EPS next 5Y - 52W High Chg -17.00%
Recommedations 2.50 Quick Ratio 5.52 Shares Outstanding 279.35M 52W Low Chg 376.00%
Insider Own 0.32% ROA -8.49% Shares Float 247.85M Beta 1.17
Inst Own 86.52% ROE -19.88% Shares Shorted/Prior 20.61M/20.64M Price 17.17
Gross Margin 26.42% Profit Margin -25.56% Avg. Volume 6,453,858 Target Price 25.50
Oper. Margin 22.88% Earnings Date Feb 28 Volume 5,319,396 Change -5.89%
About ImmunoGen, Inc.

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

IMGN Chatroom

User Image Night_Owl_Biotech Posted - 2 days ago

The attached graph compares the revenue estimates prepared by $IMGN, $RETA & $KRTX per their respective 14A filings to $ITCI analyst consensus revenue estimates through the year 2032. The graph then assumes ITCI annual sales growth of 2.0% for the year 2033 thru Caplyta patent expiration in 8/2039. Analysts forecast ITCI to generate more revenues than RETA & IMGN as prepared by RETA & IMGN management. If valuations are predicated on anticipated future revenues, does this mean ITCI warrants a higher valuation in a theoretical M&A transaction? We do not know the answer. Our next post will compare gross margin forecasts from 14A filings compared to ITCI (using ITCI's actual FY2023 gross margin profile at 92.7%). The gross margin graph looks more or less like the attached sales graph here. We own ITCI so we have every motive to see ITCI trade higher. It is also possible the graphs are inaccurate as we've made mistakes before. As always, do your own due diligence.

User Image FE123 Posted - 2 days ago

$IOVA Come on Folks $IMGN sold For $32! We’ve got so much more Potential!!

User Image BioSensai Posted - 4 days ago

$NVCT This is a 5-10x on data. $imgn was worth over $1b cap after their positive 1b data release

User Image GPS_OS_21_vs_SOC_5 Posted - 5 days ago

$IMGN $XBI $SLS $BTC.X

User Image Night_Owl_Biotech Posted - 5 days ago

$IMGN was acquired for an enterprise value of $9.6B ($10.1B purchase price less $500MM cash in the bank) which was 7.9 times its FY28 revenue estimate of $1.221B, as prepared by IMGN management per IMGN's 14A filing. The attachment compares IMGN's management prepared revenue forecast to $SWTX & $IOVA analyst consensus revenue estimates via graph thru FY28. IMGN forecasts its revenues to peak in FY36 (we assume, but can't confirm, due to IMGN's patents expiring around then). SWTX's Ogsiveo patent is good thru FY42 & ReNeu thru FY43. IOVA's Gen 2 TIL patents are anticipated to be valid thru 1/38. SWTX's gross margin should be consistent with IMGN as both sell pills. If anyone is aware of any IOVA guidance around its anticipated gross margins please share. The potential valuation related data points are included on the attachment on the table to the left. This is not investment advice. As always, we could be wrong because we've been wrong many times before.

User Image FE123 Posted - 6 days ago

$IOVA $IMGN with same amt of Shares after approval went over $20 in few months then came back down to $14 and bought out at $31

User Image GPS_OS_21_vs_SOC_5 Posted - 6 days ago

@cea You are doing yeoman's work, educating naivé retail only. _every one else knows $MRK isn't going to Comment on the CSPTA with SLS - even though the results are better than a 10.1 B Drug Elahere $IMGN and the P2 data, again, confirmed GPS Immunotherapy is tied directly to Relapse Prevention and Extended Overall Survival. PS EVERY ONE KNOWS @MBA_Certified is lying short tool. @MBA_Certified @HeavyBagHolder69 @holdinglongandstrong

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Share Price will be Much Higher this quarter. We have Phase 3 Results due this quarter - In Q1 - its Feb 18. FDA Approval, per the SAP Nov 2022 - Requires Gps Immunotherapy treatment overall Survival of 12.6 months vs Control arm at 8 or less. Based On All known Data Points Gps os is about 24 months, close to the Statistically Significant P2 results. https://www.reddit.com/r/sellasLifescience/comments/1atpds1/i_strongly_believe_gps_will_achieve_its_end_point/?utm_source=share&utm_medium=web2x&context=3 Been Invested here for a Long Time. Have eaten many miles of road dirt -- and it's time to Get Paid. $BTC.X $IMGN $XBI

User Image Badrabitt Posted - 1 week ago

$IMGN Signal alert 3.85 in oct

User Image Txtrader80 Posted - 1 week ago

My 3rd hit stock for FDA approval. $IMGN, $ARDX and now $IOVA. lets see this push past $16-$18 Tuesday.

User Image BioSensai Posted - 1 week ago

$NVCT This is a $50 stock if response data is north of 40%. Very comparable to $imgn

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Max of 6 weeks for 100x + plus roi potential - not a typo - Sls nano-cap $30m - Getting an fda green light in Q1 for an Immunotherapy that will treat 25,000 AML Remission patients. - $6b tam - is worth $24b to big pharma using a Standard 4x price to sales ratio. $IMGN $10.1b buyout. Gps achieved better results 42m shares float 75m shares fully loaded Bottom Line: sls shares will be worth much, much more within this quarter when the unblinded, phase 3, Fda registrational results are announced -in q1. Its Feb 16 $XBI $BTC.X

User Image StockInvest_us Posted - 1 week ago

Signal alert: $IMGN - GoldenStar https://stockinvest.us/l/sbDwnNHi9V

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Max of 6 weeks for 100X + PLUS ROI Potential Not a Typo SLS MCAP $30M An Approved Immunotherapy that will treat 25,000 AML Remission patients. $6B TAM - is worth 24B To BIG PHARMA using a Standard 4X Price to Sales Ratio. $IMGN 10.1B Buyout for PROC/ Gps achieved Better Results 42M shares Float 75M Shares fully loaded Bottom Line: SLS Shares Will Be Worth Much, Much More within This Quarter When the Unblinded, Phase 3, Fda Registrational results are announced -in Q1. $XBI $bit.X Something very similar will be happening here.

User Image BioSensai Posted - 1 week ago

$NVCT 68% insider owned with 1b data coming out in less than 3 weeks. $imgn was worth $1bb after their 1b for similar market and size

User Image ViractaTrader77 Posted - 1 week ago

$ADCT $AMAM $CRBP $IMGN $VINC

User Image ViractaTrader77 Posted - 1 week ago

$CRBP had a $35 million market cap before ADC Phase 1 dose escalation data was released. Now stock has a market cap of $230 million. $VINC is in the same spot their drug conjugate VIP236 Phase 1 dose escalation done in March. VIP236 has Enhertu like strength in early data. Expecting a nice run similar to CRBP. CEO is an all-star biotech CEO having been CMO at Pharmacyclics and CEO at Acerta (Acqd for $28 billion in aggregate). See attached CRBP chart before and after data release of orr of 43% and 3 partial responses out of 18. $ADCT $AMAM $IMGN

User Image Ridiculous78 Posted - 1 week ago

@Stocktradamu5 One of my biggest holdings at around $9, admittedly I took profit at $14 today. Will be back in once it goes under $10 again. I was early to $IMGN and $AMAM before the buyouts. $GLSI and $ERNA are my next two best bets for buyout candidate. $GLSI a better chance near term because it’s late Phase 3 with incredible results over SoC for BC reoccurrence prevention.

User Image BioSensai Posted - 1 week ago

$NVCT Should see much higher than $10 on data readout. $imgn was worth $1b after their 1b readout

User Image ViractaTrader77 Posted - 1 week ago

$VINC $HOLO If we break $2.59 the pathway up gets a lot easier. Stock hasn’t seen $2++ in years! Last raise was at $14.50 and Point72 still long. No warrant overhang! This baby ready to explode on VIP236 data!!!!! Ceo sold his last freaking co for $7 billion large! Going on like donkey Kong. $CRBP $IMGN

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS Green in a Sea of BIO Blood. $XBI Says a lot. Unblinded Phase 3 Results are Now Due. @DaytradingCo The CCO published analog pricing comps starting at 260k per patient, and a market scope w 10,000 aml second remission patients each year who will be immediately eligible. $2.6B Total Addressable Market Big Pharma market caps are 4x Price to Sales - 10B In max Value just for Cr2 Then Add Cr1 - 15,000 More AML First Remission patients. Other Indications Platinum Resistant Ovarian Cancer +12K Elehere was just approved w 16.46 months of OS in this indication, and $IMGN got bought for 10.1B. The numbers are Large. Then add 009 $KURA $SNDX 2 menin inhibitor companies, with Only Phase 2 Trials, are each worth nearly $2B

User Image ViractaTrader77 Posted - 1 week ago

$IMGN $VINC Congrats on the buyout guys as shareholders of $AMAM and $IMGN check out this next generation ADC company it’s market cap is only $33 million and ceo sold his last biotech for $7 billion. Could be next big thing.

User Image HaltTradeAlert Posted - 1 week ago

$IMGN Halt Time: 19:50:00 Issue Symbol: IMGN Reason Code: T12 Stock Price: $31.23 Market Cap: 8.724B Volume: 48,606,862 Relative Volume: 5.43 Shares Float: 247.85M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image moonbear Posted - 1 week ago

$IMGN My best trade in the past year. Got it in the 14s and just held quietly. Moving on now

User Image Rkramden7 Posted - 1 week ago

$IMGN anyone know when we will have $ in our accounts??? Thanks

User Image G101SPM Posted - 1 week ago

$IMGN $31.23 last sale. DAC (dollar average cost) $1.93. Original purchase at $4.14 on 4.11.23). Sold 10% to cover original cost at $29.52 (1.4.24). BRIEF-AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to trade on the NASDAQ stock exchange prior to market open on February 12, 2024.

User Image maikelm82 Posted - 1 week ago

$IMGN acquisition completed by $ABBV next up is $CERE to be finalized for $45

User Image DonCorleone77 Posted - 1 week ago

$ABBV $IMGN AbbVie completes the acquisition of ImmunoGen AbbVie (ABBV) announced that it has completed its acquisition of ImmunoGen (IMGN). With the completion of the acquisition, ImmunoGen is now part of AbbVie. AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to trade on the NASDAQ stock exchange prior to market open on February 12. AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term.

User Image Stock_Titan Posted - 1 week ago

$ABBV $IMGN AbbVie Completes Acquisition of ImmunoGen https://www.stocktitan.net/news/ABBV/abb-vie-completes-acquisition-of-immuno-vzsiy0l9qkor.html

User Image JesseNiven1 Posted - 2 weeks ago

$PINS $IMGN $MRVL I’ve made $147,883.65 with their alerts, Big thanks to this chat room. Make as much as you want[] https://profitable-trading-community.daytrading.network

Analyst Ratings
Piper Sandler Neutral Dec 4, 23
Barclays Equal-Weight Dec 4, 23
Barclays Equal-Weight Dec 1, 23
Jefferies Hold Dec 1, 23
Guggenheim Neutral Dec 1, 23
BMO Capital Market Perform Dec 1, 23
HC Wainwright & Co. Neutral Nov 30, 23
Goldman Sachs Neutral Nov 20, 23
Deutsche Bank Buy Nov 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Feb 02 Sell 29.3 4,583 134,282 73,274 02/06/24
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Feb 02 Option 0 14,350 77,857 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Feb 02 Sell 29.3 12,027 352,391 21,039 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Feb 02 Option 0 29,640 33,066 02/06/24
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 02 Sell 29.28 20,107 588,733 584,397 02/06/24
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 02 Option 0 51,234 604,504 02/06/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Feb 02 Sell 29.3 2,631 77,088 14,723 02/06/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Feb 02 Option 0 8,435 17,354 02/06/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Jan 16 Sell 29.64 187,667 5,562,450 3,426 01/18/24
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Jan 16 Option 5.28 187,667 990,882 191,093 01/18/24
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Dec 29 Option 5.32 30,000 159,600 63,140 01/03/24
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Dec 22 Sell 29.74 6,548 194,738 8,452 12/27/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Dec 22 Option 0 15,000 15,000 12/27/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Dec 15 Sell 29.4 117,445 3,452,883 2,811 12/19/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Dec 15 Option 4.94 117,445 580,178 120,256 12/19/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 30 Sell 29.20 3,826 111,719 33,140 12/05/23
Peterson Kristine Director Director Nov 30 Sell 28.9 20,000 578,000 12/05/23
Peterson Kristine Director Director Nov 30 Option 11.59 20,000 231,800 20,000 12/05/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 29 Sell 22.81 171,216 3,905,437 2,811 12/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 29 Option 10.7 171,216 1,832,011 167,235 12/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 15 Sell 15.85 166,725 2,642,591 2,811 11/17/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 15 Option 4.55 166,725 758,599 169,536 11/17/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 15 Sell 16.02 108,609 1,739,916 36,966 11/17/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Nov 15 Option 6.31 108,609 685,323 115,189 11/17/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 07 Sell 16.66 19,517 325,153 2,811 11/08/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Nov 07 Option 10.65 19,517 207,856 22,328 11/08/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Nov 06 Sell 15.29 219,545 3,356,843 11/08/23
Lentini Renee VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER Nov 06 Option 7.05 120,528 849,722 219,545 11/08/23
Wallace Richard John Director Director Nov 07 Option 14.70 10,000 147,000 10,000 11/08/23
Goldberg Mark Alan Director Director Oct 30 Option 14.89 20,000 297,800 60,151 11/01/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Sep 15 Sell 15.44 192,013 2,964,681 2,811 09/19/23
Wingrove Theresa SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS Sep 15 Option 3.43 108,668 372,731 194,824 09/19/23
Peterson Kristine Director Director Sep 13 Option 15.39 20,000 307,800 09/14/23
MCCLUSKI STEPHEN C Director Director Sep 13 Option 15.38 20,000 307,600 09/14/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Sep 12 Option 4.28 25,141 107,603 99,017 09/14/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 09 Sell 14.2 100,210 1,422,982 10,960 08/11/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 09 Option 4.92 100,210 493,033 111,170 08/11/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 02 Sell 17.59 84,581 1,487,780 10,960 08/04/23
Coen Stacy Ann SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER Aug 02 Option 4.92 84,581 416,139 91,286 08/04/23
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 02 Sell 17.29 3,007,554 52,000,609 553,270 08/04/23
Enyedy Mark J CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 02 Option 4.97 3,119,375 15,503,294 1,545,667 08/04/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Aug 02 Sell 17.55 148,277 2,602,261 22,843 08/04/23
Lentini Renee PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. Aug 02 Option 3.98 199,310 793,254 73,876 08/04/23
FOSTER DAVID G V.P.-Fin., Prin. Acc.. V.P.-Fin., Prin. Acctg. Off. Jan 04 Sell 6.38 11,052 70,512 37,912 01/04/21